HC Wainwright Reiterates “Buy” Rating for Precigen (NASDAQ:PGEN)

Precigen (NASDAQ:PGEN)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $6.00 price objective on the biotechnology company’s stock, up from their previous price objective of $4.00. HC Wainwright’s price target indicates a potential upside of 331.65% from the company’s current price. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at ($0.01) EPS, FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $7.00.

Precigen Trading Up 3.7 %

Precigen stock opened at $1.39 on Thursday. Precigen has a 12 month low of $0.65 and a 12 month high of $1.93. The business’s fifty day simple moving average is $0.94 and its two-hundred day simple moving average is $1.06. The company has a market capitalization of $407.09 million, a price-to-earnings ratio of -2.53 and a beta of 1.65.

Institutional Trading of Precigen

A number of institutional investors have recently made changes to their positions in PGEN. Iridian Asset Management LLC CT grew its stake in shares of Precigen by 82.5% during the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after purchasing an additional 1,706,815 shares during the period. LexAurum Advisors LLC grew its position in Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 417,055 shares during the period. Geode Capital Management LLC increased its holdings in Precigen by 4.8% during the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after buying an additional 149,829 shares during the last quarter. Renaissance Technologies LLC raised its position in Precigen by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after acquiring an additional 130,500 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Precigen by 11.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 127,467 shares during the period. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.